Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31425668 | 0.82 | ACHE (0.54) | ACHECA1CA2CA7CA9 | |
| SCHEMBL1157811 | 0.82 | ACHE (0.54) | ACHECA1CA2CA7CA9 | |
| SCHEMBL3164341 | 0.82 | ACHE (0.54) | ACHECA1CA2CA7CA9 | |
| SCHEMBL24433577 | 0.80 | ACHE (0.52) | ACHECA1CA2CA7CA9 | |
| SCHEMBL29974516 | 0.80 | CYP1A2 (0.58) | ACHECA1CA2CA7CA9 | |
| SCHEMBL1145531 | 0.80 | CYP1A2 (0.58) | ACHECA1CA2CA7CA9 | |
| SCHEMBL1203595 | 0.78 | ACHE (0.50) | ACHECA1CA2CA7CA9 | |
| SCHEMBL644602 | 0.78 | ACHE (0.50) | ACHECA1CA2CA7CA9 | |
| SCHEMBL1713113 | 0.78 | ACHE (0.50) | ACHECA1CA2CA7CA9 | |
| SCHEMBL10709610 | 0.78 | MTNR1A (0.57) | ACHECA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108440375-A | Using disulfide as the catalysis oxidation synthetic method of the 3- sulfydryl indole class compounds of sulphur source | 浙江工业大学 | 2018-08-24 | — | — | CN | disclosed |
| US-20030162798-A1 | Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments | ASTRAZENECA AB. | 2003-08-28 | — | — | US | disclosed |
| EP-0946562-B1 | PYRROLO[3,4-d]PYRIMIDINONE DERIVATIVES AND THEIR USE AS IMMUNOSUPPRESSANTS | ASTRAZENECA AB (SE) | 2002-03-27 | — | — | EP | disclosed |
| US-20020025966-A1 | Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments | ASTRAZENECA AB. | 2002-02-28 | — | — | US | disclosed |
| US-6306863-B1 | TREATMENT OF ASTHMA WITH CAMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-23 | — | — | US | disclosed |
| US-6229013-B1 | PRODUCED BY HYDROGENATION AND DEHALOGENATION IN THE PRESENCE OF A CATALYST; ANTIINFLAMMATORY AGENTS, IMMUNOSUPRESSANTS, ANTIPROLIFERATIVE AGENTS, ANTICARCINOGENIC AGENTS, AND TREATMENT OF RHEUMATIC DISEASE | ASTRAZENECA UK LIMITED (GB) | 2001-05-08 | — | — | US | disclosed |
| US-6211368-B1 | HYDROLYSIS OF CORRESPONDING ESTER | ASTRAZENECA UK LIMITED (GB) | 2001-04-03 | — | — | US | disclosed |
| US-6166206-A | Pyrrolo[3,4-D]Pyrimidinone derivatives and their use as medicaments | ASTRAZENECA UK LIMITED (GB) | 2000-12-26 | — | — | US | disclosed |
| US-6136974-A | Pyrrolo[3,4-D]Pyrimidinone derivatives and their use as medicaments | ASTRAZENECA UK LIMITED (GB) | 2000-10-24 | — | — | US | disclosed |
| US-6046204-A | Pyrrolo[3,4-D] pyrimidinone derivatives and their use as medicaments | ASTRA PHARMACEUTICALS LIMITED (GB) | 2000-04-04 | — | — | US | disclosed |
| EP-0946562-A1 | PYRROLO 3,4-$i(D)]PYRIMIDINONE DERIVATIVES AND THEIR USE AS MEDICAMENTS | Astra Pharmaceuticals Limited (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028301-A1 | PYRROLO[3,4-D]PYRIMIDINONE DERIVATIVES AND THEIR USE AS MEDICAMENTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162798-A1 | Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments | DPYD, TYMP, THPO | ACHE 3854/4885CA1 4826/4885CA2 3490/4885 |
| US-20020025966-A1 | Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments | DPYD, TYMP, THPO | ACHE 3854/4885CA1 4826/4885CA2 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.